Spine Update: BMP Use Continues to Expand
Executive Summary
Medtronic recently declared that InFUSE, the company's blockbuster spine bone graft product that provides the growth factor rhBMP-2 as part of a lumbar fusion cage, was well on its way to becoming standard of care in spine surgery. The company's success has fueled interest in a plethora of potential entrants into the biologic bone formation market.
You may also be interested in...
Stryker: The New Dealmakers in Orthopedics
Once known for its conservative culture, Stryker has emerged in recent years as one of orthopedics' most aggressive dealmakers. Bryant Zanko, VP of Business Development, talks about Stryker's change of direction and the strategy behind it.
Kyphon's Move Into the Mainstream
Though extremely successful in both clinical and financial terms, Kyphon faces a challenge: how to move from its lucrative niche more into the mainstream of spine therapy. The company's plan: to establish itself as a leader in the field of minimally-invasive spine surgery.
Spine-Bending Market
Today, the market for spine surgery is growing by more than 20% annually based on fusion technologies alone, despite the fact that those technologies are decades old and flawed. However, a heightened awareness of the clinical drawbacks of fusion is fueling prolific company creation in a new spine motion preservation segment of the industry. Some 118 start-ups in spine are dotting the landscape. Many hope to offer new devices that address spinal joint reconstruction; artificial discs, disc nuclei, annulus repair, facet joint replacement, and dynamic or flexible stabilization of the spine.